New drug combo shows promise in tough breast cancer
NCT ID NCT03414684
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times
Summary
This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin) helps people with metastatic triple-negative breast cancer live longer without their disease getting worse. About 78 participants with advanced breast cancer that has spread will receive either carboplatin alone or carboplatin plus nivolumab. The main goal is to see if the combination improves progression-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
Milford, Massachusetts, 01757, United States
-
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
Dana-Farber/New Hampshire Oncology-Hematology
Londonderry, New Hampshire, 03053, United States
-
Eastern Maine Medical Center
Bangor, Maine, 04401, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
St. Elizabeth's Medical Center
Boston, Massachusetts, 02135, United States
-
The Stamford Hospital
Stamford, Connecticut, 06904, United States
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
Conditions
Explore the condition pages connected to this study.